JP2011503039A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503039A5
JP2011503039A5 JP2010532625A JP2010532625A JP2011503039A5 JP 2011503039 A5 JP2011503039 A5 JP 2011503039A5 JP 2010532625 A JP2010532625 A JP 2010532625A JP 2010532625 A JP2010532625 A JP 2010532625A JP 2011503039 A5 JP2011503039 A5 JP 2011503039A5
Authority
JP
Japan
Prior art keywords
kit
polynucleotide
composition
interferon
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010532625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503039A (ja
Filing date
Publication date
Priority claimed from ES200702961A external-priority patent/ES2336873B1/es
Application filed filed Critical
Publication of JP2011503039A publication Critical patent/JP2011503039A/ja
Publication of JP2011503039A5 publication Critical patent/JP2011503039A5/ja
Pending legal-status Critical Current

Links

JP2010532625A 2007-11-07 2008-11-07 癌治療用医薬組成物 Pending JP2011503039A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200702961A ES2336873B1 (es) 2007-11-07 2007-11-07 Composicion farmaceutica para el tratamiento de cancer.
PCT/ES2008/000693 WO2009060112A1 (es) 2007-11-07 2008-11-07 Composición farmacéutica para el tratamiento de cáncer

Publications (2)

Publication Number Publication Date
JP2011503039A JP2011503039A (ja) 2011-01-27
JP2011503039A5 true JP2011503039A5 (enExample) 2011-12-22

Family

ID=40351964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010532625A Pending JP2011503039A (ja) 2007-11-07 2008-11-07 癌治療用医薬組成物

Country Status (11)

Country Link
US (1) US20110059045A1 (enExample)
EP (1) EP2223701A1 (enExample)
JP (1) JP2011503039A (enExample)
CN (1) CN101951955A (enExample)
AU (1) AU2008324056A1 (enExample)
BR (1) BRPI0820351A2 (enExample)
CA (1) CA2705105A1 (enExample)
ES (1) ES2336873B1 (enExample)
MX (1) MX2010005086A (enExample)
RU (1) RU2010122934A (enExample)
WO (1) WO2009060112A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103611163A (zh) * 2011-09-05 2014-03-05 韩美科学株式会社 一种包含干扰素α-缀合物的抗癌用药物组合物
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
TWI718086B (zh) * 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
US20170000850A1 (en) * 2013-12-20 2017-01-05 National University Of Singapore Differentiation therapy with cd137 ligand agonists
WO2016156291A1 (en) 2015-03-31 2016-10-06 F. Hoffmann-La Roche Ag Antigen binding molecules comprising a trimeric tnf family ligand
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
WO2019104716A1 (en) * 2017-12-01 2019-06-06 Adagene Inc. Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
EP1851244A4 (en) * 2005-02-15 2009-04-15 Gtc Biotherapeutics Inc ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF
NZ568433A (en) * 2005-10-21 2012-07-27 Gtc Biotherapeutics Inc Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use

Similar Documents

Publication Publication Date Title
JP2011503039A5 (enExample)
JP2008507536A5 (enExample)
Ciardiello et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
Liepelt et al. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases
Arnaldez et al. Targeting the insulin growth factor receptor 1
JP2013507439A5 (enExample)
JP2012067116A5 (enExample)
RU2010122934A (ru) Фармацевтическая композиция для лечения злокачественных опухолей
JP2020510662A5 (enExample)
JP2014076062A5 (enExample)
JP2009505676A5 (enExample)
JP2015512860A5 (enExample)
KR101993963B1 (ko) 항 종양제 및 항 종양 효과 증강제
Aoki et al. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
JP2012034692A5 (enExample)
JP2008500815A5 (enExample)
JP2017506217A5 (enExample)
IL292193B2 (en) Anti-b7-h1 antibodies for treating tumors
JP2013509429A5 (enExample)
ME02806B (me) Protutijela protiv csf-1r
JP2013503202A5 (enExample)
JP2006524246A5 (enExample)
JP2017514800A5 (enExample)
JP2019506862A5 (enExample)
JP2014507412A5 (enExample)